D-1360-2016 Class II Terminated
FDA drug recall D-1360-2016 was initiated by Pharmedium Services, LLC on May 5, 2016 and is designated Class II. Reason for recall: Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs. The recall status is terminated (terminated Mar 6, 2018). Affected quantity: 177 Medical Cassettes.
Recall Details
- Product Type
- Drugs
- Report Date
- Jul 27, 2016
- Initiation Date
- May 5, 2016
- Termination Date
- Mar 6, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 177 Medical Cassettes
Product Description
0.03% Bupivacaine HCl (Preservative Free) in Sodium Chloride 0.9%, 250 mL Medical Cassette Reservoir, Rx Only, Compounded by PharMEDium Services, LLC, Memphis, TN 36141, NDC 61553-931-11
Reason for Recall
Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.
Distribution Pattern
Nationwide
Code Information
Lot # 160410097M; Exp. 05/16 Lot # 160420107M; Exp. 05/16 Lot # 160460117M; Exp. 05/16 Lot # 160530133M; Exp. 05/16 Lot # 160540206M; Exp. 05/16 Lot # 160570008M; Exp. 05/16 Lot # 160670132M; Exp. 06/16 Lot # 160700001C; Exp. 06/16 Lot # 160770020C; Exp. 06/16 Lot # 160900103C; Exp. 06/16
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1360-2016
- openFDA file date
- Oct 27, 2026
- Loaded by RegDataLab
- Oct 29, 2026